BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240409
DTEND;VALUE=DATE:20240412
DTSTAMP:20260515T225720
CREATED:20240116T093630Z
LAST-MODIFIED:20240116T093700Z
UID:38503-1712620800-1712879999@www.pharmajournalist.com
SUMMARY:Measuring Patient Engagement Summit
DESCRIPTION:The Measuring Patient Engagement Summit is the definitive conference for practical answers. This event will act as the honeypot gathering for leading patient engagement experts to share their latest experiences of how they are successfully measuring patient engagement to: inform decision making in improving patient engagement\, quantify the impact of patient engagement on recruitment and retention\, and ensure the most meaningful outreach to patients and advocacy groups. \n \nJoin 70+ Chief Patient Officers\, Patient Engagement leaders and Patient Advocacy experts\, from esteemed pharmaceutical and biotech companies\, such as Novartis\, Otsuka\, Boehringer Ingelheim\, AstraZeneca and many more\, to establish a roadmap to quantify the success of your patient engagement work. \n  \nCheck out the full event guide now: https://ter.li/cqba4m
URL:http://www.pharmajournalist.com/event/measuring-patient-engagement-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240416
DTEND;VALUE=DATE:20240419
DTSTAMP:20260515T225720
CREATED:20231215T122902Z
LAST-MODIFIED:20231215T123125Z
UID:38368-1713225600-1713484799@www.pharmajournalist.com
SUMMARY:3rd ADC Analytical Development Summit
DESCRIPTION:The 3rd ADC Analytical Development Summit is your only industry-dedicated meeting providing you with the key insights to ensure you are developing a high-quality ADC product within regulatory boundaries. \nNext year’s program promises to give you even more focused content to better quantify DAR and drug distribution\, overcome species separation challenges\, and better utilize impurity assays to measure free-linker drug and process-related impurities. \nGet an exclusive sneak peek of the agenda here. \nNot only is this meeting packed with technical content that will allow you to influence\, gain a deeper understanding\, and improve product quality\, but it will also give you the opportunity to interact with industry experts including: \n\nNailing Zhang\, Lead Biologist\, FDA\nLinda Nelson\, Executive Director\, RA-CMC\, Daiichi Sankyo\nDavid Lee\, Executive Director\, Analytical Chemistry\, Mersana Therapeutics\nChris Woods\, Scientist\, Analytical Development\, Seagen\nMadhumati Mukherjee\, Senior Scientist\, AstraZeneca\nDengyun (Daisy) Sun\, Principal Scientist\, Cell Based Sciences\, Merck & Co.\nYan-Hui Liu\, Director\, Analytical Development\, GlaxoSmithKline\n\n…and many more! \nSee the full speaker lineup and agenda sessions here. \nWe hope you can join us to network with like-minded colleagues and scientists and have the in-depth technical conversations needed to address the common analytical bottlenecks in ADC development.
URL:http://www.pharmajournalist.com/event/3rd-adc-analytical-development-summit/
LOCATION:Hilton Boston Bay Back\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240416
DTEND;VALUE=DATE:20240419
DTSTAMP:20260515T225720
CREATED:20240111T102149Z
LAST-MODIFIED:20240326T141147Z
UID:38478-1713225600-1713484799@www.pharmajournalist.com
SUMMARY:4th Fc-Mediated Function Summit
DESCRIPTION:Discover & Shape the Future of Biologics & Antibody Therapies at the 4th Fc-Mediated Function Summit \nFINAL 5 PASSES REMAINING – Register Now at https://ter.li/g5st7q \nAt the intersection of groundbreaking research\, clinical innovation\, and collaborative networking\, the 4th Fc-Mediated Function Summit stands as a beacon for advancing the frontier of FcRn\, FcγR\, and IgG therapeutics. Our mission is to supercharge molecular development\, elevate clinical utility\, and explore novel therapeutic applications through a comprehensive understanding of targets and biology. \nIn a landscape where clinical data is expanding\, and partnerships like the Argenx-Genmab powerhouse exemplifying the potential of antibody therapies\, the spotlight on biologics Fc modulation as a therapeutic target has been more intense than ever. The 4th Fc-Mediated Function Summit continues to be at the forefront of this movement\, uniting experts and enthusiasts alike. \nKey Highlights: \nTargeting FcRn & FcγR Biology: \nUnlock the secrets of molecular engineering and real-world clinical outcomes by focusing on the critical targets – FcRn and FcγR. Gain insights into the intricacies of their biological pathways\, and understand how molecular modifications can translate into tangible clinical benefits. \nUnrivaled Content: \nAs the only conference dedicated exclusively to FcRn\, this meeting will comprehensively cover the landscape. Attendees can expect to be immersed in cutting-edge research\, the latest advancements\, and a holistic understanding of the subject matter. This focus ensures that participants are at the forefront of knowledge and equipped with insights that are not diluted by unrelated topics\, setting this summit apart as a beacon of specialized expertise. \nExceptional Networking: \nForge meaningful connections with a diverse cohort of professionals spanning immunology\, antibody engineering\, pharmacology\, toxicology\, and immuno-oncology. The summit provides a unique opportunity to engage with 80+ peers\, facilitating cross-disciplinary partnerships and knowledge exchange.
URL:http://www.pharmajournalist.com/event/4th-fc-mediated-function-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240416
DTEND;VALUE=DATE:20240419
DTSTAMP:20260515T225720
CREATED:20240213T101859Z
LAST-MODIFIED:20240213T101859Z
UID:38680-1713225600-1713484799@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Muscular Disorders
DESCRIPTION:Discover the forefront of gene therapy at the 4th Gene Therapy for Muscular Disorders Summit (April 16-18\, Boston). Following the groundbreaking approval of Sarepta’s DMD gene therapy in June 2023\, our April 2024 gathering explores key challenges in translating research into clinical breakthroughs. With a sharp focus on safety and efficacy\, we unite experts to advance transformative treatments for muscular disorders lacking viable options. Join us to propel innovation forward and make a tangible impact on patient care. This is your opportunity to shape the future of muscular disorder treatments in just one event. \nWant to learn more? Check out the event guide here: https://ter.li/cjxppp
URL:http://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-muscular-disorders/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240422
DTEND;VALUE=DATE:20240425
DTSTAMP:20260515T225720
CREATED:20240125T115520Z
LAST-MODIFIED:20240125T115520Z
UID:38573-1713744000-1714003199@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes and Injectable Drug Devices East Coast Conference and Exhibition
DESCRIPTION:SAE Media Group’s 11th Annual Pre-Filled Syringes East Coast Conference will return to Boston in April 2024 to bring you the latest advances in the combination product drug delivery space. The 2024 conference will be bigger and better than ever\, bringing you 3 days of expertise\, comprising of a pre-conference focus day exploring the advances in PFS design for enhanced drug delivery proceeded by a two-day main conference with morning keynote plenaries and parallel afternoon topic streams addressing the industry’s hottest topics through case studies and industry insights. \nThis event will not only bring you key insights needed to expand and enhance your injectable device portfolio but will also give you the opportunity to network with key players throughout the industry. We hope to welcome you to this must attend event in April 2024! \nWhy attend: \n\n3 full days of networking opportunities\n40+ presentations with 75% of speakers from the top 20 big pharma companies\nThe agenda has been curated by an advisory board of big pharma and biotech opinion leaders providing expertise focused on device development\, regulatory affairs and quality\nAccess a focus day and 4 dedicated streams addressing the hottest topics in the industry\n\nThis year’s agenda has been validated by our 2024 advisory board: \nJohn Schalago\, Executive Director\, Senior Global Program Director\, Novartis\nKhaudeja Bano\, Vice President\, Combination Product Quality\, Amgen\nJames P. Wabby\, Global Head\, Regulatory Affairs – Emerging Device Technologies and Combination Products\, AbbVie\nMark DeStefano\, Director\, Combination Products and Devices R&D\, Teva\nMichael Song\, Director\, Drug Product Development\, Moderna \nWhat you will gain: \n\nCollaborate with pharma\, biotech and device developers across 3 full days on the latest trends\, advancements and challenges within the pre-filled syringe and injectable device market\nHear about new technological advances for challenging to delivery drugs such as large volume\, highly viscous and lyophilised formulations with case studies on wearable injectors and more\nUnderstand the latest regulatory requirements from experts surrounding combination products and engage in opportunities for collaboration and needs for advancing innovation in the field with an advisory board fireside chat\nGain insight into how big pharma is incorporating sustainable approaches into drug device design and lifecycle management\nDelve into the growing potential of digital health to improve patient experience and treatment\, and the challenges facing its implementation\nExamine how container and packaging development can support the ever-evolving innovations drug development\, including case studies on CCIT in deep-cold storage and formulator perspectives\n\nTo know more visit: www.pfsamericas.com/PharmaJournalist-Event-Listing
URL:http://www.pharmajournalist.com/event/pre-filled-syringes-and-injectable-drug-devices-east-coast-conference-and-exhibition/
LOCATION:Boston\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240423
DTEND;VALUE=DATE:20240426
DTSTAMP:20260515T225720
CREATED:20240103T125432Z
LAST-MODIFIED:20240103T131021Z
UID:38428-1713830400-1714089599@www.pharmajournalist.com
SUMMARY:5th TCR-based Therapies for Solid Tumors Summit
DESCRIPTION:The 5th TCR-based Therapies for Solid Tumors Summit returns is back as the exclusive gathering where TCR pipelines take center stage. It serves as the premier platform for networking with biopharma industry leaders dedicated to expediting the clinical and commercial development of TCR-based therapeutics. \nThis summit serves as the epicenter for exploring these transformative advancements\, poised to showcase the long-term efficacy of TCR therapies in the treatment of solid tumors\, marking a monumental milestone in the field’s evolution. \nThis is your opportunity to accelerate next generation TCR engineering\, enhance target identification\, & improve solid tumor persistence to transform clinical & scalable development for patients in need. Join TScan Therapeutics\, Marengo Therapeutics\, T-Cypher Bio and more to gain invaluable insights into the future of TCR-based therapies. \nFind out more here: https://ter.li/f8jhfw
URL:http://www.pharmajournalist.com/event/5th-tcr-based-therapies-for-solid-tumors-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240423
DTEND;VALUE=DATE:20240426
DTSTAMP:20260515T225720
CREATED:20240117T110146Z
LAST-MODIFIED:20240131T105720Z
UID:38516-1713830400-1714089599@www.pharmajournalist.com
SUMMARY:2nd mRNA Process Development & Manufacturing Summit Europe
DESCRIPTION:As European biopharma seek regulatory clarity to progress their mRNA process development and manufacturing\, the 2nd mRNA Process Development & Manufacturing Summit Europe returns to help you improve and optimise purification processes\, platforms for circular and saRNAs and drug product formulation. \nWhere: Crowne Plaza Frankfurt – Congress Hotel\, Frankfurt\, Germany \nWhen: 23-25th April\, 2024 \nWebsite: https://ter.li/d3ggdb \n \nReuniting directors\, heads and senior scientists pioneering the European mRNA space\, this three-day industry forum will navigate key bottlenecks from mRNA sequence design to in vitro transcription and scaling up processes. \n\nGain clarity on regulatory quality standards and comparability changes with the MHRA and CureVac\nExplore continuous platform technologies to accelerate low cost manufacturing\nGlean insights into purification and computational modelling approaches to optimise downstream processes\nHarness platform technologies for circular and self-amplifying RNAs to enhance their manufacturability\nImprove your drug product formulation and manufacturing for personalised mRNA-based medicines\n\nWhat’s next:  \n\nDownload your copy of the brochure: https://ter.li/d3ggdb\nRegister your place: https://ter.li/lzwg6z
URL:http://www.pharmajournalist.com/event/2nd-mrna-process-development-manufacturing-summit-europe/
LOCATION:Crowne Plaza Frankfurt – Congress Hotel\, Lyoner Str. 44 -48\, Frankfurt am Main\, 60528\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240423
DTEND;VALUE=DATE:20240426
DTSTAMP:20260515T225720
CREATED:20240123T114632Z
LAST-MODIFIED:20240126T122455Z
UID:38558-1713830400-1714089599@www.pharmajournalist.com
SUMMARY:Exosome Characterization & Analytical Development Summit
DESCRIPTION:In the ever-evolving exosome field\, the past year has witnessed remarkable progress. From Kimera’s FDA IND approval to Brexogen’s recent deal with HK inno.N and advancements in analytical technology\, the landscape is rapidly advancing. Developing robust techniques is increasingly crucial\, serving as the cornerstone for exosome therapeutics\, alongside drug delivery applications and advancements. \n \nThe Exosome Characterization & Analytical Development Summit offers a comprehensive forum\, equipping you with the skills needed to establish robust techniques\, select the best instruments\, ensure quality\, and seamlessly navigate regulatory processes. \nAcross three days in April\, this hotly anticipated summit will unite key experts from AbbVie\, Aegle Therapeutics\, Vesigen Therapeutics\, and more to unite an industry on: \n\nIn depth technical content of exosome analysis and parameters for confidence in quality\nDefining standardized tools and techniques while keeping regulatory guidance in mind for clinical progression\nBridging communications and networking between Analytical Experts and Decision Makers\n\nTo learn more\, and secure your place\, check out the official event website here: https://ter.li/v1xubp \nDownload the full event guide here: https://ter.li/182ula
URL:http://www.pharmajournalist.com/event/exosome-characterization-analytical-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240423
DTEND;VALUE=DATE:20240426
DTSTAMP:20260515T225720
CREATED:20240213T103635Z
LAST-MODIFIED:20240213T103635Z
UID:38695-1713830400-1714089599@www.pharmajournalist.com
SUMMARY:Peptide Based Therapeutics Summit
DESCRIPTION:Positioned in the goldilocks spot between small molecules and biologics\, peptide therapeutics have undergone an exciting uphill trajectory within the last decade. Fuelled by advances in synthesis and screening technologies\, together with novel design and delivery strategies to surmount their inherent drawbacks\, this modality is showing new levels of promise. The momentum behind this exciting modality is evidenced in the billion-dollar deals from industry giants such as Genentech and Merck\, signalling a surge in interest from an expanding array of companies venturing into the field of next-generation peptide-based drugs. \nThe first industry-focused event dedicated towards this exciting new modality\, the Peptide Based Therapeutics Summit will unite pioneers from Johnson & Johnson\, Fog Pharma\, Genentech & PeptiDream\, spanning diverse diseases and therapeutic approaches. Whether you’re focused on peptide-drug conjugates\, bicyclic or macro-cyclic peptides\, PCSK9\, GLP\, or any other peptide based therapeutic\, this is an invaluable opportunity to learn from peers\, accelerate discovery and de-risk the development of your peptide therapeutics. \nAs we enter the third wave of peptide-based therapeutics\, this therapeutic and disease agnostic meeting will bring together the leading minds in early discovery\, pre-formulation\, heads of peptide drug development and pioneering peptide chemists. Together\, we will dissect challenges related to improving peptide stability\, raising oral bioavailability and balancing cell permeability with intracellular target selectivity\, as well as exploring how the latest cutting-edge technology can help you arrive at the optimal lead compound. \nLearn more about this meeting that helps to shape the trajectory of these remarkable drugs across various therapeutic landscapes: https://ter.li/2qs54c
URL:http://www.pharmajournalist.com/event/peptide-based-therapeutics-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240429
DTEND;VALUE=DATE:20240503
DTSTAMP:20260515T225720
CREATED:20231124T115148Z
LAST-MODIFIED:20231124T115309Z
UID:38225-1714348800-1714694399@www.pharmajournalist.com
SUMMARY:3rd LNP Formulation & Process Development Summit
DESCRIPTION:Following the success of the first 2 years of the LNP Formulation & Process Development Summit\, we are hugely excited to announce the much-anticipated return of this world-leading summit in 2024. \nThis April\, the 3rd LNP Formulation & Process Development Summit returns to Boston\, bringing together over 400 experts in LNP Biology\, Chemistry\, Formulation\, Analytical Development\, Process Development\, Manufacturing and more. This is your ultimate platform for sharing insights\, learning new concepts and networking to propel more LNPs into the clinic in 2024. \nJoin the ever-growing community of LNP pioneers as they tackle the challenges associated with developing safe\, compliant and efficacious LNPs\, to treat a variety of disease indications at a variety of target organs. This starts with the in vitro discovery of LNPs through to the manufacturing processes\, with end-to-end synergy fundamental. \nHear from industry powerhouses Pfizer\, Moderna\, Alnylam and more\, as well as new companies to share their insights to this community including Capstan Therapeutics\, AbbVie\, Mana Bio\, Serina Therapeutics\, Karma Biotechnologies and more. \nWith an expanded content offering and a 4-track\, 4-day summit format\, we continue to be the most comprehensive\, premium LNP content available to industry. Part of this year’s content growth\, the addition of the ‘LNP IP & Commercial Partnerships Focus Day’ has evolved with the current industry trends to secure long standing partnership to demonstrate clinical results\, as well as gaining a further handle on the current IP and legal landscape. \nTo know more visit: https://ter.li/s96la3
URL:http://www.pharmajournalist.com/event/3rd-lnp-formulation-process-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR